Drug Profile
Rizatriptan
Alternative Names: L 705126; Maxalt; Maxalt-MLT; MK 0462; MK 462; Rizatriptan benzoateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antimigraines; Small molecules; Triazoles; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- No development reported Motion sickness
Most Recent Events
- 08 Apr 2021 Discontinued - Phase-III for Migraine (In adolescents, In children) in India (PO)
- 01 Sep 2020 Launched for Migraine (In adolescents, In children) in Romania, United Kingdom, Poland, Estonia, France (PO) prior to September 2020
- 31 Aug 2020 Registered for Migraine (In adolescents, In children) in United Kingdom, France, Estonia, Poland, Romania (PO) prior to August 2020